Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Multicenter Study to Establish the Safety and Efficacy of Ceftobiprole Medocaril Compared With Vancomycin Plus Aztreonam in the Treatment of Acute Bacterial Skin and Skin Structure Infections

Trial Profile

A Randomized, Double-blind, Multicenter Study to Establish the Safety and Efficacy of Ceftobiprole Medocaril Compared With Vancomycin Plus Aztreonam in the Treatment of Acute Bacterial Skin and Skin Structure Infections

Recruiting
Phase of Trial: Phase III

Latest Information Update: 14 Jan 2019

At a glance

  • Drugs Ceftobiprole (Primary) ; Aztreonam; Vancomycin
  • Indications Bacterial infections; Skin and soft tissue infections
  • Focus Registrational; Therapeutic Use
  • Sponsors Basilea Pharmaceutica
  • Most Recent Events

    • 04 Jan 2019 According to a Basilea Pharmaceutica media release, Top line results from the study are expected in the second half of 2019.
    • 23 Feb 2018 Planned End Date changed from 1 Jan 2019 to 1 Nov 2019.
    • 23 Feb 2018 Planned primary completion date changed from 1 Nov 2018 to 1 Oct 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top